Yasushi Shimizu

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3.2K citations · Full text

Medicine, Oncology, Cancer Pharmacology +11

A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator’s choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141

Naomi Kiyota, Yasuhisa Hasegawa, Shunji Takahashi et al. · Oral Oncology · 2017 · 141 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells

Junko Kikuchi, Taichi Takashina, Ichiro Kinoshita et al. · Lung Cancer · 2012 · 116 citations · Full text

Medicine, Oncology, Pharmacology +17

Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance

Junko Kikuchi, Ichiro Kinoshita, Yasushi Shimizu et al. · Cancer · 2010 · 96 citations · Full text

Medicine, Molecular Biology, Oncology +17

Minichromosome maintenance (MCM) protein 4 as a marker for proliferation and its clinical and clinicopathological significance in non-small cell lung cancer

Junko Kikuchi, Ichiro Kinoshita, Yasushi Shimizu et al. · Lung Cancer · 2010 · 95 citations

Medicine, Molecular Biology, Oncology +12